CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant
Completed · Phase 1/Phase 2
Conditions studied: Breast Cancer
In brief
Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.
Key facts
- Study ID
- NCT00186680
- Run by
- Stanford University
- People needed
- 99
- Starts
- 1996-09-01
- Expected to finish
- 2005-06-01
- Last updated by the study team
- 2010-03-02
Who can join
Age: 19 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Stanford University School of Medicine — Stanford, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.